恒瑞医药：获得HRS-6209胶囊和HRS-2189片药物临床试验批准通知书 前者国内外尚无同类产品获批上市

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of two new drugs, HRS-6209 and HRS-2189, which are aimed at treating advanced malignant tumors [2] Group 1: Drug Development - HRS-6209 is a novel selective CDK4 inhibitor intended for the treatment of advanced malignant solid tumors, with no similar products approved for market domestically or internationally [2] - HRS-2189 is a new KAT6 inhibitor also aimed at treating advanced malignant tumors, with no drugs targeting the same pathway approved for market domestically or internationally [2]